FDA's Center for Drug Evaluation and Research approved fewer new treatments in 2019.
Formulary Watch
Latest News
All News
Advertisement
Global market for peanut allergy treatments estimate at $4.5 billion.
A new class of drugs for high cholesterol and a novel peanut allergy treatment lead expected approvals.
Novel cancer drug snags FDA approval.
Traditional party drug known as ecstasy is undergoing clinical trials to assist in PTSD treatment.
Lamotrigine was contaminated with a heart drug.
Ozempic’s approval follows Jardiance’s expanded heart indication last July.
Already approved for adult patients, Fiasp is now available for children.
Major depression drug recalled over wrong dosage.
Pfizer bucks the trend with as high as 98.5% price cuts.
Advertisement
Approval of Ubrelvy follows several new migraine drugs.
Diabetes and hypertension are among the primary diseases included.
The fish oil drug is approved to reduce cardiovascular risk.
Alkermes omitted warnings about serious risks from taking the drug.
Stephen Hahn is confirmed by the U.S. Senate.
Hospitals sue over drug price disclosure rule.
This is the agency’s first generic approvals of Gilenya.
Approval made via international collaborative effort.
Federal subpoenas are latest in opioid actions.
FDA cites 15 companies making unsubstantiated health claims.
PBM mergers contribute to pricing problems, ACP says.
Trump claims lower drug prices, fights Pelosi bill.
FDA and Congress are putting forth new proposals to mitigate drug shortages, which continue to have a major impact on the US healthcare system.
Pharma maker develops biosimilars to Lucentis, Eyelea.
Sandoz now has 2 biosimilars to the popular cancer drug.
Health groups had urged Trump to make a different choice.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
ALK Testing Strategies and Navigating First-Line Treatment Options in Advanced NSCLC
2
ALK-Positive NSCLC: Epidemiology, Prognosis, and the Critical Role of Biomarker Testing
3
How PBMs are tackling behavioral health
4
Most commercial plans cover SC and IV oncology therapies at parity
5